chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Two days after receiving the janssen COVID-19 vaccine my right eye started having blurred vision now I am completely blind and cannot see out of it.
POPPED A BLOOD VESSEL; BRUISING OF ARM; FLU LIKE SYMPTOMS (FEVER AND BODY ACHES); This spontaneous report received from a patient concerned a female of unspecified age. The patient's height, and weight were not reported. The patient's concurrent conditions included thyroid issues. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808609 expiry: UNKNOWN) dose was not reported, administered on 26-MAR-2021 16:15 on left arm for prophylactic vaccination. No concomitant medications were reported. On 27-MAR-2021, the subject experienced popped a blood vessel. On 27-MAR-2021, the subject experienced bruising of arm. On 27-MAR-2021 at around 2:30, the subject experienced flu like symptoms (fever and body aches). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from flu like symptoms (fever and body aches) on 27-MAR-2021 07:30, and the outcome of popped a blood vessel and bruising of arm was not reported. This report was non-serious.; Sender's Comments: V0: Medical assessment comment not required as per standard procedure as case assessed as non-serious.
No additional adverse effects reported; Administered an expired dose of properly storedd rotateq; product used for unapproved age; This spontaneous report was received from a nurse, referring to a 6-month-old infant of unknown gender. Information regarding the patient's pertinent medical history, concurrent condition, drug reactions/allergies and concomitant medication were not provided.  On 23-APR-2020, the patient was administered an expired dose of properly stored rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (strength and dose were not reported, lot# R016790; expiry date reported and validated as 20-APR-2020) for prophylaxis (product administered to patient of inappropriate age and expired product administered). This was the patient's second dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ). No additional adverse effects were reported. There was no associated product quality complaint.
Iron deficient anemia- found during an appointment for leukocytosis Shortness of breath, fatigue, brittle nails
became pale; nausea; vomited; This spontaneous report was received from a medical assistant referring to a 4-year-old female patient. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 10-FEB-2020, the patient was vaccinated with measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (recombinant human albumin (rHA)) (PROQUAD) (strength, dose, frequency, dosing schedule were not reported) via subcutaneous route (lot # S017265 and expiration date 01-DEC-2020) which was reconstituted with sterile diluent (lot # R020229 and expiration date 08-NOV-2020) for prophylaxis. Other suspect therapies included: On 10-FEB-2020, the patient was vaccinated with diphtheria toxoid, pertussis acellular 5-component vaccine, poliovirus vaccine inactivated (MRC-5), tetanus toxoid (QUADRACEL) (strength, dose, route, dosing schedule, lot # and expiration date were not reported) for prophylaxis. On 10-FEB-2020, after administration of measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (PROQUAD), the patient became pale, had nausea and vomited. The patient went to the emergency room for observation and she was treated with epinephrine (EPIPEN). On 11-FEB-2020, the outcome of the events were recovered. The causality assessment between the suspect therapy and the events were not reported.
Patient was supposed to receive booster, however an additional dose of the primary series was given mistakenly. No adverse effect reported after contacting parent. Informed booster may be received after 2 months
Flu-like symptoms including fever and headache; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu-like symptoms including fever and headache) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In May 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In May 2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms including fever and headache). At the time of the report, INFLUENZA LIKE ILLNESS (Flu-like symptoms including fever and headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-May-2021, Prostatic specific antigen: 3.73 Result: 3.73. On 11-May-2022, Prostatic specific antigen: 4.43 (High) Elevated to 4.43. On 10-Jun-2022, Prostatic specific antigen: 4.64 (High) measured at 4.64.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications details were not reported by the reporter.  Reportedly, the symptoms occurred the same day as the injection, but much later in the day around 8-9 PM. It was stated that these symptoms that had experienced were typical to what he had reading on all the websites.   Additionally, Patient had been going to receive PSA tests for his prostate for the past 10 years and over the past 2-3 years he had been going to receive these tests more often and was scheduled to had this test at the beginning of MAY. Patient had discussed these findings with his urologist who recommended to received an MRI of his prostate and also had been following the research of another urologist online who had been seeing similar trends in patients after vaccination.   Patient had not taken any medications or treatments for any of his symptoms.   This case was linked to MOD-2022-588201, MOD-2022-588203, MOD-2022-588204, MOD-2022-588207 (Patient Link).
Janssen 3/15/21, 12/20/21. Positive on 12/4/22
This spontaneous report as received from a pharmacist refers to an approximately 77 years old female patient with some allergies but unspecified, who on 23-NOV-2012, was vaccinated with 0.65 ml dose of ZOSTAVAX (lot H018091, 04-JAN-2014), subcutaneously on her left arm. No other co-suspects were reported. No concomitant medications were reported. In November 2012, the patient developed a blood red eye, unspecified which eye and also a rash that the pharmacist might be on the both sides of the patient's face but the pharmacist was insure. The patient's husband went to the pharmacy over the weekend to get VALTREX prescription filled for his wife. The pharmacist stated that the patient was seen by an eye specialist and was being treated with erythromycin ophthalmic ointment. It was reported that the cause of the red eye was unknown at the time of report. The pharmacist stated she called the patient and she was feeling okay but the symptoms remain the same. Additional information has been requested.
Perceived headache starting about 10 minutes post administration. Discussed treatment with Acetaminophen and/or Ibuprofen OTC. Pt unsure if headache due to stress or vaccination.
No additional AE details or PQC.; 33 year old patient who received PROQUAD; This spontaneous report was received from a medical assistant and refers to a 33-year-old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On 29-OCT-2021, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) lot # T032148, expiration date 20-MAR-2022, 0.5 milliliter (formulation, concentration, dose number, route of administration and anatomical location were not reported) for prophylaxis (product administered to patient of inappropriate age). No additional adverse event was reported.
12 Feb 4PM left arm swollen, red, and itchy at infection site. 13 Feb 8 am woke up to itchy rash/ hives on stomach, back, buttocks, and legs. Took benadryl until 17 Feb symptoms didn't get better. I went to urgent care and received a steroid shot and prescription antihistamine.  The itchiness and redness decreased later that night.  The rash/hives are still present but, starting to go away.
Pt recvd vax 13FEB92 PM , pt extremely irritable that noc; woke in morning w/hive-like red rash on cheeks & arms; Seen by MD who felt it was poss rxn (mild) to vax (DTP); no fever; pts rash & irritability gone by 17FEB92;
6cm x 7cm circular area of erythema.  Pt has a mild local systemic reaction.
The rash is located on his chest, back, buttocks, rear thighs, rear knees, his arms ,and some on his/a skin rash that is deteriorating; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 72 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 11May2021 11:00 (Lot number: EW0179) at the age of 72 years as dose 1, single and administered in arm right, administration date 05Jun2021 (Lot number: EW0182) as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: RASH (non-serious) with onset 12May2021, outcome "not recovered", described as "The rash is located on his chest, back, buttocks, rear thighs, rear knees, his arms ,and some on his/a skin rash that is deteriorating". Therapeutic measures were taken as a result of rash.  No follow-up attempts are possible. No further information is expected.
Developed cellulitis at injection site. It should be noted that injection was to be given intramuscularly but the RN who administered it gave to the back of the arm which was likely subcutaneous rather than  intramuscular.
pt exp diarrhea, h/a, nausea, inc temp, vaginal bleeding small & large volumes; sx cont p/plane trip inc bruisability on calves;
Approx 18 hours post-vac, I began to experience joint/muscle pain and fever. Pain and fever escalated over next 24 hours, with fever reaching 101.5F and pain in elbows, hips, knees that severely restricted mobility. Has begun to abate, but joint pain remains.
Moderate period cramping and bleeding. This is completely irregular for me. These pains are much more intense than typical camping and period is was 100% unexpected. Had just finished last period the week before. Cycle is consist and and regular other than this.
No additional AE.; administered Improperly Stored M-M-R II lot; This spontaneous report has been received from a registered nurse referring a patient of unknown age and gender patient. The pertinent medical history, drug reactions, allergies and concomitant medications were not reported.  On an unspecified date on October 2022 (also reported as 05-OCT-2022, 06-OCT-2022, 07-OCT-2022, 11-OCT-2022, 13-OCT-2022, 14-OCT-2022, 18-OCT-2022, 20-OCT-2022, 24-OCT-2022) the patient was vaccinated with an improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection, lot number W009107 with expiration date 04-DEC-2023, administered for prophylaxis (strength, specific dosage, vaccination scheme, route of administration and anatomical site of application were not provided) (product storage error).   The administered vaccine experienced a temperature excursion of 47.5 degree fahrenheit (F) for 5 minutes. There was no previous temperature excursion. No additional adverse event reported.   This is one of several reports from same reporter.
Diagnosed with positive COVID-19 a few days after receiving the first dose of Moderna COVID19 vaccine; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Diagnosed with positive COVID-19 a few days after receiving the first dose of Moderna COVID19 vaccine) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2021, the patient experienced COVID-19 (Diagnosed with positive COVID-19 a few days after receiving the first dose of Moderna COVID19 vaccine). At the time of the report, COVID-19 (Diagnosed with positive COVID-19 a few days after receiving the first dose of Moderna COVID19 vaccine) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Feb-2021, SARS-CoV-2 test: positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
fully covid vaccinated since 2/22/2021.  tested positive for covid 5/10/21.
Slight chills; General malaise; Skin was extremely hot to touch; Dose 3/booster dose administration on 07Oct2021; This is a spontaneous report from a contactable nurse, the patient. A 67-year-old non-pregnant female patient received third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 07Oct2021 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included lisinopril (MANUFACTURER UNKNOWN) 40 mg one tablet daily for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9267) via an unspecified route of administration in the right arm on 04Feb2021 as a single dose for COVID-19 immunisation and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9267) via an unspecified route of administration in the left arm on 26Feb2021 as a single dose for COVID-19 immunisation. On 08Oct2021 at 06:00, within 24 hours after vaccination, the patient experienced slight chills, general malaise and her skin was extremely hot to touch. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events slight chills, general malaise and skin was extremely hot to touch was resolved on 09Oct2021 at 10:00.  The lot number for BNT162b2 was not provided and will be requested during follow up.
This spontaneous report was received from a doctor of pharmacy refers to an approximately 57 year old female patient with no drug reactions or allergies who on an unknown date, was vaccinated intramuscularly in her right arm with a dose of ZOSTAVAX (dose and lot number not reported). No other co-suspects were reported. No concomitant medications were reported. The pharmacist reported that the patient developed pain, redness and swelling in her right arm where the vaccine was administered. The pharmacist mentioned that these symptoms started the day after the patient received the vaccine on an unspecified date and clarified that the vaccine was not administered in her pharmacy. No treatment was given for the experience. No lab diagnostics studies were performed. At the time of the report, the patient was recovering. The patient sought medical attention through the pharmacist. The relatedness for patient developed pain, swelling and redness in her right arm where the vaccine was administered was unknown for ZOSTAVAX. Additional information has been requested.
Received a call 1650 c/o tongue swollen and feeling like it has "pins and needles". Denies any difficulty breathing. Able to speak clearly without any audible signs of distress.  Received dose of vaccine at 1600 today.  Originally called our call center who instructed her to call 911.She refused stating she just wanted to take Benadryl. Call transferred to me.  Instructed that per our Emergency medical orders, Benadryl is for urticaria, not for swelling of airway.  Instructed to call 911. She declined stating she wanted to try Benadryl first. Explained that a blocked airway can happen fast and she doesn't want to risk waiting too long.  Epi is recommended. She states she has a severe allergy to bees (which she did not list on the registration form--so only had a 15 minute wait versus 30 after her injection)--She states she has 6 epi pens readily available with her.  Confirms she has someone there with her. Instructed that my recommendation would be to call 911, but if she isn't going to do that she needs to have her epi pens ready and available and ensure that the person she is with knows how to use them. If she develops any trouble breathing, they need to give epi and call 911, then repeat dose every 5-10 minutes until paramedics arrive. She agrees with that plan.  Agrees to have another nurse call her later to f/u.  Called again several times that evening by RN--at 1735 she was advised to use her epi pen and call 911, she declined. She finally had boyfriend drive her to ER to "sit in parking lot" in case something got worse. enc to have boyfriend go into ER and alert them. RN also called ER to give them an alert.  Continued to decline to use Epi pen.  Declined to let RN speak to boyfriend either.  Rn tried to call her later and she didn't answer.  RN left a message, but she didn't call back.
noticed a mild rash (looks like sunburn) near where my armpit/boob meet on the side where I got a shot/I feel good and only noticed the rash when I got out of the shower; This is a spontaneous report received from a non-contactable consumer. A 46-year-old female patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration on 03Apr2021 (Batch/Lot number was not reported) at single dose for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient stated after her first dose of vaccine on 03Apr2021, she "noticed a mild rash (looks like sunburn) near where her armpit/boob meet on the side where she got a shot". On 06Apr2021, patient stated she felt good and only noticed the rash when she got out of the shower. No pain or itchiness with it. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Parent was driving patient home when patient had a seizure with vomiting. Parent called 911 - patient was tranported to Emergency Department
Acute onset of hives, wheels, urticaria, dermatographia which started 14 days following the Moderna booster dose. Now remains as CHRONIC hives, urticaria, pruritus, and dermatographia which still continues.  Elevation on serum creatinine levels compared to patients baseline.
This spontaneous report as received from a male consumer over his 50 years old reporting on himself. In 2012, "over 5 months ago", the consumer was vaccinated with a dose of GARDASIL (route, dose and Lot # not reported0. No adverse event was reported. Additional information is not expected.
Fatigue, chills, body aches, elevated body temp (don't have access to thermometer, so exact temp could not be determined) - all symptoms onset 36 hours post injection and only lasted 12 hours from onset.
Parent's other son, now 16, had an adverse reaction to his measles-mumps-rubella (MMR) vaccine when he was younger, and has not been vaccinated since; This spontaneous report was received from a consumer through a online article. Mother says hospital clueless about reporting to vaers regarding a currently 16 year old male patient. Information regarding the patient's pertinent medical history, concomitant therapies, drug reactions, or allergies was not reported.     On an unknown date,(reported as when he was younger) the patient´s mother reported her son was vaccinated with an unspecified measles-mumps-rubella MMR vaccine (dose, route of administration, vaccination scheme frequency, anatomical location, lot number and expiration date were not reported) and experienced and adverse reaction (vaccination complication) to it. It was reported the patient has not been vaccinated since. The outcome of the event was not reported.  The consumer's causality assessment between the measles-mumps-rubella MMR vaccine  and the vaccination complication was related.
BLURRY VISION; WEAKNESS; FELT SICK; TIRED; COULDN'T MOVE; DIZZY; This spontaneous report received from a patient concerned a 47 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included non-alcoholic, non-smoker, no cholesterol, and varicose veins, and other pre-existing medical conditions included no known drug allergies and had a watch on eating. family history of varicose veins, thrombosis and blood clots. patient is healthy and exercise regularly. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805031, and expiry: UNKNOWN) dose was not reported, administered on 15-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 16-MAR-2021, the subject experienced couldn't move. On 16-MAR-2021, the subject experienced dizzy. On 16-MAR-2021, the subject experienced felt sick. On 16-MAR-2021, the subject experienced tired. On 18-MAR-2021, the subject experienced blurry vision. On 18-MAR-2021, the subject experienced weakness. Treatment medications (dates unspecified) included: ascorbic acid/ergocalciferol/folic acid/nicotinamide/panthenol/retinol/riboflavin/thiamine hydrochloride. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from couldn't move, felt sick, and tired, had not recovered from dizzy, and the outcome of blurry vision and weakness was not reported. This report was non-serious.
Patient was given Td vaccine and in about 4 to 5 minutes later he was given PNEUMOVAX. After PNEUMOVAX, patient stated that he felt very hot, broke out in rash and turns red. Patient was given 50mg BENADRYL injection, oxygen and IV fluids and is now in stable condition.
TWINRIX give IM in the dorsogluteal, should be given in the deltoid. 1st dose must be repeated.
Convulsions, totally shaking all night. Body soaked in sweat almost had to call 911.
At 12:50 pm pt came back into clinic and complained of chest pain. Had just come back into school from play ground. BP 150/84 P 104. Had pt. lie down on lot and EMS checked and monitored pt. Had pt get up and walk around. After resting. Stated she felt fine and was released to her grandmother's care to go home.